Table 1.
Derivation cohort (n=2 343 759) |
Validation cohort (n=1 267 159) |
|
---|---|---|
Women | 1 189 845 (50.8) | 645 012 (50.9) |
Mean (SD) age (years) | 48.1 (14.3) | 48.0 (14.2) |
Mean (SD) Townsend score | −0.2 (3.4) | −0.3 (3.5) |
Smoking status: | ||
Non-smoker | 1 176 386 (50.2) | 631 545 (49.8) |
Former smoker | 356 697 (15.2) | 193 974 (15.3) |
Current smoker (amount not recorded) | 99 100 (4.2) | 59 178 (4.7) |
Light smoker (<10 cigarettes/day) | 142 369 (6.1) | 71 037 (5.6) |
Moderate smoker (10-19/day) | 175 419 (7.5) | 91 679 (7.2) |
Heavy smoker (≥20/day) | 136 202 (5.8) | 74 056 (5.8) |
Smoking status not recorded | 257 586 (11.0) | 145 690 (11.5) |
Ethnic group: | ||
White or not recorded | 2 229 834 (95.1) | 1 219 987 (96.3) |
Indian | 22 598 (1.0) | 7 577 (0.6) |
Pakistani | 11 137 (0.5) | 3 663 (0.3) |
Bangladeshi | 6 432 (0.3) | 2 632 (0.2) |
Other Asian | 12 581 (0.5) | 5 032 (0.4) |
Caribbean | 13 454 (0.6) | 4 666 (0.4) |
Black African | 20 801 (0.8) | 9 471 (0.8) |
Chinese | 5 915 (0.3) | 3 068 (0.2) |
Other | 21 007 (0.9) | 11 063 (0.8) |
Clinical conditions: | ||
Treated hypertension* | 132 585 (5.7) | 67 986 (5.4) |
Type 2 diabetes | 40 504 (1.7) | 20 868 (1.7) |
Family history of early coronary heart disease† | 247 981 (10.6) | 143 593 (11.3) |
Atrial fibrillation | 12 031 (0.5) | 6 589 (0.5) |
Chronic renal disease | 3 594 (0.2) | 1 917 (0.2) |
Clinical values: | ||
Systolic blood pressure recorded | 2 027 470 (86.5) | 1 081 944 (85.4) |
Mean (SD) systolic blood pressure (mm Hg) | 131.9 (20.5) | 131.7 (20.5) |
BMI recorded | 1 773 567 (75.7) | 949 434 (74.9) |
Mean (SD) BMI (kg/m2) | 26.1 (4.5) | 26.1 (4.5) |
Smoking status and BMI recorded | 1 754 250 (74.9) | 937 808 (74.0) |
Serum total and HDL cholesterol recorded | 692 590 (29.6) | 354 853 (28.0) |
Mean (SD) total cholesterol:HDL cholesterol ratio | 4.2 (1.3) | 4.2 (1.3) |
BMI=body mass index; HDL=high density lipoprotein.
*A recorded diagnosis of hypertension and treatment that could include angiotensin converting enzyme inhibitors, angiotensin receptor blockers, aldosterone antagonists, β blockers, thiazides, or calcium channel blockers.
†Heart disease in a first degree relative aged <60 years.